Compendium of Cancer Genome Aberrations

STBT5:Solitary fibrous tumour: Difference between revisions

[unchecked revision][unchecked revision]
← Older editNewer edit →
VisualWikitext
Line 53: Line 53:
|Positive (universal)||CD34
|Positive (universal)||CD34
|-
|-
|Positive (universal)||STAT6
|Positive (universal)||STAT6 (nuclear)
|-
|-
|Negative (universal)||
|Negative (universal)||
Line 69: Line 69:
!Notes
!Notes
|-
|-
|<span class="blue-text">EXAMPLE:</span> t(9;22)(q34;q11.2)||<span class="blue-text">EXAMPLE:</span> 3'ABL1 / 5'BCR||<span class="blue-text">EXAMPLE:</span> der(22)||<span class="blue-text">EXAMPLE:</span> 20% (COSMIC)
|inv(12)(q13q13)||3'STAT6 / 5'NAB2||NA||55-100%
<span class="blue-text">EXAMPLE:</span> 30% (add reference)
|Yes  
|<span class="blue-text">EXAMPLE:</span> Yes
|Unknown
|<span class="blue-text">EXAMPLE:</span> No
|No
|<span class="blue-text">EXAMPLE:</span> Yes
|Many different breakpoints in the exons and introns are associated with this fusion. Ex: ''NAB2''ex4-''STAT6''ex2; ''NAB2''ex6-''STAT6''ex16/17
|<span class="blue-text">EXAMPLE:</span>
The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference).
|}
|}
==Individual Region Genomic Gain / Loss / LOH==
==Individual Region Genomic Gain / Loss / LOH==
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable. Do not delete table.'') </span>
 
 
Not Applicable
{| class="wikitable sortable"
{| class="wikitable sortable"
|-
|-
Line 114: Line 114:
|}
|}
==Characteristic Chromosomal Patterns==
==Characteristic Chromosomal Patterns==
Put your text here <span style="color:#0070C0">(''EXAMPLE PATTERNS: hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis. Do not delete table.'')</span>
 
 
Not Applicable
{| class="wikitable sortable"
{| class="wikitable sortable"
|-
|-
Line 141: Line 143:
!Notes
!Notes
|-
|-
|<span class="blue-text">EXAMPLE:</span> ''TP53''; Variable LOF mutations
|
<span class="blue-text">EXAMPLE:</span>
 
''EGFR''; Exon 20 mutations
 
<span class="blue-text">EXAMPLE:</span> ''BRAF''; Activating mutations
|<span class="blue-text">EXAMPLE:</span> TSG
|<span class="blue-text">EXAMPLE:</span> TSG
|<span class="blue-text">EXAMPLE:</span> 20% (COSMIC)
|<span class="blue-text">EXAMPLE:</span> 20% (COSMIC)
Line 158: Line 155:
|}Note: A more extensive list of mutations can be found in cBioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.
|}Note: A more extensive list of mutations can be found in cBioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.
==Epigenomic Alterations==
==Epigenomic Alterations==
Put your text here
Not Applicable
==Genes and Main Pathways Involved==
==Genes and Main Pathways Involved==
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Can include references in the table. Do not delete table.'')</span>
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Can include references in the table. Do not delete table.'')</span>
Line 165: Line 162:
!Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome
!Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome
|-
|-
|<span class="blue-text">EXAMPLE:</span> ''BRAF'' and ''MAP2K1''; Activating mutations
|NAB2::STAT6; Activating mutation
|<span class="blue-text">EXAMPLE:</span> MAPK signaling
|EGR Pathway
|<span class="blue-text">EXAMPLE:</span> Increased cell growth and proliferation
|Increased activation of EGR1
|-
|-
|<span class="blue-text">EXAMPLE:</span> ''CDKN2A''; Inactivating mutations
|<span class="blue-text">EXAMPLE:</span> ''CDKN2A''; Inactivating mutations
Retrieved from "https://test.ccga.io/index.php/STBT5:Solitary_fibrous_tumour"